IDYA
Price
$35.68
Change
+$0.27 (+0.76%)
Updated
Dec 24 closing price
Capitalization
3.13B
96 days until earnings call
Intraday BUY SELL Signals
VRTX
Price
$462.99
Change
+$3.78 (+0.82%)
Updated
Dec 24 closing price
Capitalization
117.47B
41 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs VRTX

Header iconIDYA vs VRTX Comparison
Open Charts IDYA vs VRTXBanner chart's image
IDEAYA Biosciences
Price$35.68
Change+$0.27 (+0.76%)
Volume$355.13K
Capitalization3.13B
Vertex Pharmaceuticals
Price$462.99
Change+$3.78 (+0.82%)
Volume$310.23K
Capitalization117.47B
IDYA vs VRTX Comparison Chart in %
IDYA
Daily Signal:
Gain/Loss:
VRTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IDYA vs. VRTX commentary
Dec 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and VRTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 25, 2025
Stock price -- (IDYA: $35.68 vs. VRTX: $462.99)
Brand notoriety: IDYA and VRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 35% vs. VRTX: 22%
Market capitalization -- IDYA: $3.13B vs. VRTX: $117.47B
IDYA [@Biotechnology] is valued at $3.13B. VRTX’s [@Biotechnology] market capitalization is $117.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 3 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • VRTX’s FA Score: 3 green, 2 red.
According to our system of comparison, VRTX is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while VRTX’s TA Score has 4 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 4 bearish.
  • VRTX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, VRTX is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а +5.78% price change this week, while VRTX (@Biotechnology) price change was +3.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

VRTX is expected to report earnings on Feb 04, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRTX($117B) has a higher market cap than IDYA($3.13B). IDYA YTD gains are higher at: 38.833 vs. VRTX (14.971). VRTX has higher annual earnings (EBITDA): 4.66B vs. IDYA (-204.84M). VRTX has more cash in the bank: 6.29B vs. IDYA (787M). IDYA has less debt than VRTX: IDYA (27.2M) vs VRTX (1.84B). VRTX has higher revenues than IDYA: VRTX (11.7B) vs IDYA (215M).
IDYAVRTXIDYA / VRTX
Capitalization3.13B117B3%
EBITDA-204.84M4.66B-4%
Gain YTD38.83314.971259%
P/E RatioN/A32.58-
Revenue215M11.7B2%
Total Cash787M6.29B13%
Total Debt27.2M1.84B1%
FUNDAMENTALS RATINGS
IDYA vs VRTX: Fundamental Ratings
IDYA
VRTX
OUTLOOK RATING
1..100
6678
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
80
Overvalued
PROFIT vs RISK RATING
1..100
5730
SMR RATING
1..100
9442
PRICE GROWTH RATING
1..100
3923
P/E GROWTH RATING
1..100
10024
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (27) in the null industry is somewhat better than the same rating for VRTX (80) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than VRTX’s over the last 12 months.

VRTX's Profit vs Risk Rating (30) in the Biotechnology industry is in the same range as IDYA (57) in the null industry. This means that VRTX’s stock grew similarly to IDYA’s over the last 12 months.

VRTX's SMR Rating (42) in the Biotechnology industry is somewhat better than the same rating for IDYA (94) in the null industry. This means that VRTX’s stock grew somewhat faster than IDYA’s over the last 12 months.

VRTX's Price Growth Rating (23) in the Biotechnology industry is in the same range as IDYA (39) in the null industry. This means that VRTX’s stock grew similarly to IDYA’s over the last 12 months.

VRTX's P/E Growth Rating (24) in the Biotechnology industry is significantly better than the same rating for IDYA (100) in the null industry. This means that VRTX’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAVRTX
RSI
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
42%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
63%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
57%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
56%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
58%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
64%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
59%
Declines
ODDS (%)
Bearish Trend 8 days ago
75%
Bearish Trend 8 days ago
40%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
53%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
VRTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LTPZ52.310.33
+0.63%
PIMCO 15+ Year US TIPS ETF
XLKI26.060.05
+0.19%
State Street®TechSelSectSPDR®PrmETF
SPMD59.080.09
+0.15%
State Street SPDR Port S&P 400 Md CpETF
GRNB24.430.03
+0.12%
VanEck Green Bond ETF
QTAP44.72N/A
N/A
Innovator Growth-100 Acltd Ps ETF™ April

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.76%
NUVL - IDYA
59%
Loosely correlated
+0.89%
XENE - IDYA
58%
Loosely correlated
+1.06%
XNCR - IDYA
57%
Loosely correlated
-0.13%
CGON - IDYA
55%
Loosely correlated
+0.22%
IMTX - IDYA
54%
Loosely correlated
+1.47%
More

VRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with NEVPF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRTX
1D Price
Change %
VRTX100%
+0.82%
NEVPF - VRTX
47%
Loosely correlated
N/A
SNDX - VRTX
41%
Loosely correlated
-0.46%
CRSP - VRTX
35%
Loosely correlated
+0.44%
IDYA - VRTX
33%
Loosely correlated
+0.76%
RGNX - VRTX
32%
Poorly correlated
+0.77%
More